Barinthus Biotherapeutics (BRNS) Earnings Date & Reports

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

BRNS is expected to report earnings to fall 25.86% to -36 cents per share on August 07

Barinthus Biotherapeutics BRNS Stock Earnings Reports

Q2'25

Est.

$-0.36

Q1'25

Missed

by $0.13

Q4'24

Missed

by $0.05

Q3'24

Beat

by $0.23

Q2'24

Missed

by $0.03

The last earnings report on May 07 showed earnings per share of -49 cents, missing the estimate of -36 cents. With 1.00K shares outstanding, the current market capitalization sits at 39.99M.

View a ticker or compare two or three

Compare

BRNS